🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

48 results for “msc” Clear

  1. Debamestrocel - MSC-NTF (NurOwn)

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 mab active

    1 trial

  2. Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT)

    Disc Medicine

    Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea)

    phase 3 small molecule active

    1 trial

  3. Jinarc 30 mg tablets, Tolvaptan, Jinarc 15 mg tablets, Samsca 7.5 mg tablets

    Otsuka Beijing Research Institute

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  4. MC0518, EVEROLIMUS, MYCOPHENOLIC ACID , ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    Steroid refractory Acute Graft versus host Disease

    phase 3 small molecule active

    1 trial

  5. NurOwn® (MSC-NTF cells)

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 mab completed

    2 trials

  6. Solution de chlorure de sodium à 0,9%, Allogeneic umbilical cord derived MSC (thawed and washed)

    Pari Pharma GmbH

    Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)

    phase 3 small molecule active

    1 trial

  7. 3D hypoxia-preconditioned UC-MSC group

    The First People's Hospital of Lianyungang

    Severe Aplastic Anemia (SAA)

    phase 2 small molecule active

    1 trial

  8. ACT-20-MSC

    Aspire Biopharma Holdings

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  9. ADMSC-fib safety and efficacy in patients with chronico wounds

    The George Institute

    chronic wounds

    phase 2 other active

    1 trial

  10. Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cells (MSC) ectopically expressing CXCR4 and IL10

    The George Institute

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    phase 2 small molecule active

    1 trial

  11. Allogeneic MSC (AlloMSC)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Systemic Lupus Erythematosus

    phase 2 mab active

    1 trial

  12. BM-MSCs

    The First People's Hospital of Lianyungang

    Kidney Transplantation

    phase 2 other active

    2 trials

  13. BMSC transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 other active

    1 trial

  14. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  15. HB-adMSC

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 mab terminated

    1 trial

  16. HUMSCs combined with bovine type I collagen

    The First People's Hospital of Lianyungang

    Burn Wounds

    phase 2 other active

    1 trial

  17. Human Umbilical Cord derived MSCs

    CytoMed Therapeutics Ltd

    Lupus Nephritis

    phase 2 mab active

    1 trial

  18. Infusion of MSC

    Lxo Ireland Designated Activity Company

    Discordant Immunological Response in HIV Infected Subjects

    phase 2 small molecule completed

    1 trial

  19. Intravenous administration of 1 million of MSC

    Lxo Ireland Designated Activity Company

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  20. MSC

    The Children's Hospital of Zhejiang University School of Medicine

    BPD - Bronchopulmonary Dysplasia

    phase 2 small molecule active

    1 trial

  21. MSC

    Shandong University

    Type 2 Diabetes

    phase 2 mab active

    1 trial

  22. MSC and PRP

    Hospital Authority, Hong Kong

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  23. MSC-NTF cells transplantation (IM)

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis

    phase 2 mab completed

    1 trial

  24. MSCAT-THAC Placebo, Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Systemic sclerosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources